Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 24, 2026

CRWV vs. MSFT: Which AI Infrastructure Stock is the Better Buy?

View original at finance.yahoo.com
CRWV vs. MSFT: Which AI Infrastructure Stock is the Better Buy? Behind every generative AI model and autonomous system is massive compute infrastructure, especially data centers full of GPUs that train and serve models…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Active power is expected to exceed 850 MW by year-end

    80% confidence

  • Spending on AI data centers and accelerated computing is surging, creating a multitrillion-dollar opportunity

    80% confidence

  • MSFT remains the stronger long-term buy, with AI monetization through Azure and Copilot, massive RPO visibility and diversified cash flows

    80% confidence

  • Management remains upbeat about ongoing growth across commercial and enterprise segments, driven by global capacity buildout and multiple revenue pillars

    80% confidence

  • Management remains confident in its ability to meet long-term demand, scale capacity and strengthen its position in AI cloud as new offerings, partnerships and federal deals ramp

    80% confidence

  • In terms of valuation, CRWV seems to be a better pick at the moment

    80% confidence

  • CRWV looks better positioned for near-term outperformance because we are in the AI capacity-deployment phase

    80% confidence

  • The Core Scientific acquisition decision does not affect its growth outlook

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
CRWV vs. MSFT: Which AI Infrastructure Stock is the Better Buy? — Source | Via News | ViaNews EU